On May 12, Eli Lilly announced detailed results from the SURMOUNT-5 study. The study is an open-label Phase 3b clinical trial designed to evaluate the efficacy and safety of the GLP/GLP-1 dual receptor agonist tirzepatide and the GLP-1 single receptor agonist semaglutide in overweight adults (without diabetes) who are obese or have at least one comorbidity (such as hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). At week 72, tirzepatide achieved the primary endpoint and all five key secondary endpoints, and showed superiority over semaglutide throughout the trial.